Cargando…

Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19

OBJECTIVE: To determine the association between chronic statin use and mortality in patients hospitalized with coronavirus disease 2019 (COVID-19). PATIENTS AND METHODS: We identified a retrospective cohort of patients requiring admission at the Mayo Clinic using our enterprise-wide COVID-19 registr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yetmar, Zachary A., Challener, Douglas W., Tleyjeh, Imad M., Sohail, M. Rizwan, Cerhan, James R., Badley, Andrew D., O’Horo, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955930/
https://www.ncbi.nlm.nih.gov/pubmed/33748678
http://dx.doi.org/10.1016/j.mayocpiqo.2021.02.002
Descripción
Sumario:OBJECTIVE: To determine the association between chronic statin use and mortality in patients hospitalized with coronavirus disease 2019 (COVID-19). PATIENTS AND METHODS: We identified a retrospective cohort of patients requiring admission at the Mayo Clinic using our enterprise-wide COVID-19 registry from March 1, 2020, through September 30, 2020. Available information included age, sex, use of statins, medical comorbidities, and 30-day mortality. We estimated the association of statins with 30-day mortality using odds ratios and 95% CIs from logistic regression modeling. RESULTS: Patients (N=1295) between the ages of 30 and 80 years tested positive for COVID-19 and required admission during the study period, of whom 500 (38.6%) were taking statins at admission. Patients taking statins were older and more likely to have diabetes mellitus or congestive heart failure. Within 30 days of diagnosis, 59 (4.6%) died. In multivariable analysis, statin users did not have statistically different odds of death within 30 days with an odds ratio of 1.14 (95% CI, 0.64 to 2.03; P=.67) compared to nonusers. CONCLUSION: Patients with COVID-19 taking statins had similar 30-day mortality to those not taking statins after adjusting for relevant covariates. Although this is partly influenced by a higher prevalence of risk factors for more severe COVID-19 presentation not entirely adjusted for by the Charlson comorbidity index, these data would not support statins as a likely therapeutic intervention for COVID-19 in the hospital setting.